Eva-Juliane Vollstedt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eva-Juliane Vollstedt has a total of 279 co-authors. Here are the top co-authors by number of shared publications:
- Christine Klein
Institute of Neurogenetics, University of Luebeck, Luebeck, Germany
6 shared publications - Katja Lohmann
Institute of Neurogenetics, University of Luebeck, Luebeck, Germany
4 shared publications Christine Klein
Institute of Neurogenetics University of Lübeck Lübeck Germany
3 shared publicationsMeike Kasten
Department of Psychiatry and Psychotherapy and Institute of Neurogenetics University of Lübeck Lübeck Germany
3 shared publications- Norbert Brüggemann
Department of Neurology, Section for Movement Disorders, University of Luebeck, and University Hospital Schleswig-Holstein, Luebeck, Germany
3 shared publications Shalini Padmanabhan
Discovery & Translational Research, The Michael J. Fox Foundation for Parkinson’s Research
3 shared publications
Latest Publications
- Open Access
How many do we miss? - Evaluation of age at onset and family history as selection criteria for genetic testing in Parkinson’s disease
Importance: Current recommendations for genetic testing in Parkinson’s disease (PD) prioritize groups of patients based on age at onset (AAO) and family history (FH). The increasing importance of identifying genetic PD for personalized counseling and potential gene-specific therapies calls for a data-driven evaluation of these recommendations. Objective: To estimate the diagnostic accuracy, specifically the sensitivity, specificity, and positive predictive value (PPV), of genetic testing in PD based on AAO and FH. Design, Setting, and Participants: We analyzed data from six cohorts within four independent datasets: ROPAD, PD GENEration, the MDSGene database, the Global Parkinson’s Genetics Program (GP2), and two German observational studies. These datasets included 25,063 PD participants, of whom 6,295 carried pathogenic or likely pathogenic variants. ROPAD and PD GENEration, both prospective genetic screening studies, served as representative real-world cohorts. Main Outcome(s) and Measure(s): For each gene, we quantified the proportion of carriers by age bracket and familial vs. sporadic status. Receiver operating characteristic (ROC) curves, and area under the curve (AUC) values with 95% confidence intervals (CIs) were calculated for AAO and FH. PPVs were computed based on sensitivity, specificity, and prevalence. Results: An AAO threshold of ≤50 identified 32% (ROPAD), 23% (PD GENEration), 63% (MDSGene), and 30% (GP2) of genetic cases. ROC analyses based on AAO alone yielded AUCs of 0.59 (CI: 0.57-0.60, ROPAD), 0.58 (CI: 0.56-0.60, PD GENEration), 0.78 (CI: 0.75-0.80, MDSGene), and 0.54 (CI: 0.52-0.56, GP2), respectively. Combining AAO with FH increased AUCs to 0.60 (CI: 0.59-0.62), 0.60 (CI: 0.58-0.62), 0.83 (CI: 0.81-0.85), and 0.58 (CI: 0.56-0.60). FH improved AUCs for dominant genes such as LRRK2 (e.g., 0.52 to 0.61 in ROPAD) but had minimal or no effect for recessive genes (e.g., PRKN/PINK1 : 0.90 to 0.90 in ROPAD). Conclusions and Relevance: Current selection criteria (AAO ≤50) identify only a minority (23–32%) of variant carriers. Most carriers (68–77%) present with a later AAO and remain undetected. While AAO is moderately predictive in some cohorts, it insufficiently captures late-onset genetic forms, particularly LRRK2 -PD and GBA1 -PD. The limited incremental value of FH challenges its use as a selection criterion. These findings support revised, data-driven testing strategies to improve detection of genetic PD across all age groups. Key Points: Question: What are the diagnostic accuracy, specifically the sensitivity, specificity, and positive predictive value, of the current age at onset and family history-based selection criteria for genetic testing to identify major gene pathogenic variant carriers among patients with Parkinson’s disease? Findings: Performing genetic testing in Parkinson’s disease patients with an early age at onset ≤50 years results in a positive genetic finding in one of four patients; however, this criterion captures only 23–32% of known variant carriers in population-based datasets, underscoring its limited sensitivity and leading to substantial underdiagnosis of genetic Parkinson’s disease. The additional discriminatory value of family history is marginal. Meaning: Revised recommendations for broader genetic testing in Parkinson’s disease are warranted.
Open AccessHow many do we miss? - Evaluation of age at onset and family history as selection criteria for genetic testing in Parkinson’s disease
Importance: Current recommendations for genetic testing in Parkinson’s disease (PD) prioritize groups of patients based on age at onset (AAO) and family history (FH). The increasing importance of identifying genetic PD for personalized counseling and potential gene-specific therapies calls for a data-driven evaluation of these recommendations. Objective: To estimate the diagnostic accuracy, specifically the sensitivity, specificity, and positive predictive value (PPV), of genetic testing in PD based on AAO and FH. Design, Setting, and Participants: We analyzed data from six cohorts within four independent datasets: ROPAD, PD GENEration, the MDSGene database, the Global Parkinson’s Genetics Program (GP2), and two German observational studies. These datasets included 25,063 PD participants, of whom 6,295 carried pathogenic or likely pathogenic variants. ROPAD and PD GENEration, both prospective genetic screening studies, served as representative real-world cohorts. Main Outcome(s) and Measure(s): For each gene, we quantified the proportion of carriers by age bracket and familial vs. sporadic status. Receiver operating characteristic (ROC) curves, and area under the curve (AUC) values with 95% confidence intervals (CIs) were calculated for AAO and FH. PPVs were computed based on sensitivity, specificity, and prevalence. Results: An AAO threshold of ≤50 identified 32% (ROPAD), 23% (PD GENEration), 63% (MDSGene), and 30% (GP2) of genetic cases. ROC analyses based on AAO alone yielded AUCs of 0.59 (CI: 0.57-0.60, ROPAD), 0.58 (CI: 0.56-0.60, PD GENEration), 0.78 (CI: 0.75-0.80, MDSGene), and 0.54 (CI: 0.52-0.56, GP2), respectively. Combining AAO with FH increased AUCs to 0.60 (CI: 0.59-0.62), 0.60 (CI: 0.58-0.62), 0.83 (CI: 0.81-0.85), and 0.58 (CI: 0.56-0.60). FH improved AUCs for dominant genes such as LRRK2 (e.g., 0.52 to 0.61 in ROPAD) but had minimal or no effect for recessive genes (e.g., PRKN/PINK1 : 0.90 to 0.90 in ROPAD). Conclusions and Relevance: Current selection criteria (AAO ≤50) identify only a minority (23–32%) of variant carriers. Most carriers (68–77%) present with a later AAO and remain undetected. While AAO is moderately predictive in some cohorts, it insufficiently captures late-onset genetic forms, particularly LRRK2 -PD and GBA1 -PD. The limited incremental value of FH challenges its use as a selection criterion. These findings support revised, data-driven testing strategies to improve detection of genetic PD across all age groups. Key Points: Question: What are the diagnostic accuracy, specifically the sensitivity, specificity, and positive predictive value, of the current age at onset and family history-based selection criteria for genetic testing to identify major gene pathogenic variant carriers among patients with Parkinson’s disease? Findings: Performing genetic testing in Parkinson’s disease patients with an early age at onset ≤50 years results in a positive genetic finding in one of four patients; however, this criterion captures only 23–32% of known variant carriers in population-based datasets, underscoring its limited sensitivity and leading to substantial underdiagnosis of genetic Parkinson’s disease. The additional discriminatory value of family history is marginal. Meaning: Revised recommendations for broader genetic testing in Parkinson’s disease are warranted.
- Open Access
Usage of an Alternative Translation Start Site in PRKN mutation carriers: Key to Later-Onset Parkinson’s Disease and a Novel Therapeutic Target
Biallelic pathogenic variants of PRKN, encoding the Parkin RBR E3 ubiquitin protein ligase, are the most common known cause of autosomal recessive Parkinson’s disease (PD). PARK- PRKN is characterized by an early median age at onset (AAO) of 31 years with a wide range (3-81 years). When evaluating the 16 previously published carriers of a homozygous deletion of Exon 2 ( PRKN delEx2 ) from the MDSGene database, the median AAO is later (39.5 years; range: 25-75 years) than in carriers of other PRKN pathogenic variants. Here, we investigated 26 homozygous PRKN delEx2 patients, including 20 from additional sources, and confirmed the later median AAO (37 years, range: 13-60 years). Furthermore, we investigated one carrier who was still unaffected in her 60s. To elucidate the functional basis for this observation, we used induced pluripotent stem cell (iPSC)-derived dopaminergic neurons (iDN) from this unaffected carrier as well as genome-edited iDNs from two control lines and neuroblastoma cell lines (SH-SY5Y) with the introduction of a homozygous PRKN delEx2 . We observed elevated levels of an N-terminally truncated form of Parkin (Parkin Δ1–79) , starting at an internal translation initiation site (TIS) in Exon 3 (p.Met80 in the full-length protein) in cells with the Exon 2 deletion. Furthermore, in silico prediction and Parkin quantification in isogenic neuroblastoma cell lines suggested the presence of residual Parkin Δ1–79 also for other PRKN variants upstream of the alternative TIS. iDNs from PRKN delEx2 carriers partially retained Parkin E3 ubiquitin ligase activity in contrast to carriers of other exonic deletions in PRKN ( PRKN delEx3 , PRKN delEx7 ) via the expression of Parkin Δ1–79 . Importantly, endogenous Parkin E3 ubiquitin ligase activity of Parkin Δ1–79 was enhanced in neurons derived from a homozygous PRKN delEx2 variant carrier upon treatment with a small molecule allosteric modulator of Parkin (BIO-2007817). In summary, the later AAO in patients with homozygous PRKN delEx2 is associated with partially retained Parkin function. The residual ligase activity can be further increased pharmacologically, providing mutation-specific personalized counseling opportunities and a potential novel therapy for selected patients with PARK- PRKN .
Open AccessUsage of an Alternative Translation Start Site in PRKN mutation carriers: Key to Later-Onset Parkinson’s Disease and a Novel Therapeutic Target
Biallelic pathogenic variants of PRKN, encoding the Parkin RBR E3 ubiquitin protein ligase, are the most common known cause of autosomal recessive Parkinson’s disease (PD). PARK- PRKN is characterized by an early median age at onset (AAO) of 31 years with a wide range (3-81 years). When evaluating the 16 previously published carriers of a homozygous deletion of Exon 2 ( PRKN delEx2 ) from the MDSGene database, the median AAO is later (39.5 years; range: 25-75 years) than in carriers of other PRKN pathogenic variants. Here, we investigated 26 homozygous PRKN delEx2 patients, including 20 from additional sources, and confirmed the later median AAO (37 years, range: 13-60 years). Furthermore, we investigated one carrier who was still unaffected in her 60s. To elucidate the functional basis for this observation, we used induced pluripotent stem cell (iPSC)-derived dopaminergic neurons (iDN) from this unaffected carrier as well as genome-edited iDNs from two control lines and neuroblastoma cell lines (SH-SY5Y) with the introduction of a homozygous PRKN delEx2 . We observed elevated levels of an N-terminally truncated form of Parkin (Parkin Δ1–79) , starting at an internal translation initiation site (TIS) in Exon 3 (p.Met80 in the full-length protein) in cells with the Exon 2 deletion. Furthermore, in silico prediction and Parkin quantification in isogenic neuroblastoma cell lines suggested the presence of residual Parkin Δ1–79 also for other PRKN variants upstream of the alternative TIS. iDNs from PRKN delEx2 carriers partially retained Parkin E3 ubiquitin ligase activity in contrast to carriers of other exonic deletions in PRKN ( PRKN delEx3 , PRKN delEx7 ) via the expression of Parkin Δ1–79 . Importantly, endogenous Parkin E3 ubiquitin ligase activity of Parkin Δ1–79 was enhanced in neurons derived from a homozygous PRKN delEx2 variant carrier upon treatment with a small molecule allosteric modulator of Parkin (BIO-2007817). In summary, the later AAO in patients with homozygous PRKN delEx2 is associated with partially retained Parkin function. The residual ligase activity can be further increased pharmacologically, providing mutation-specific personalized counseling opportunities and a potential novel therapy for selected patients with PARK- PRKN .
- Open Access
Understanding monogenic Parkinson's disease at a global scale
Until recently, about three-quarters of all monogenic Parkinson's disease (PD) studies were performed in European/White ancestry, thereby severely limiting our insights into genotype-phenotype relationships at global scale. The first systematic approach to embrace monogenic PD worldwide, The Michael J. Fox Foundation Global Monogenic PD (MJFF GMPD) Project, contacted authors of publications reporting individuals carrying pathogenic variants in known PD-causing genes. In contrast, the Global Parkinson's Genetics Program's (GP2) Monogenic Network took a different approach by targeting PD centers not yet represented in the medical literature. Here, we describe combining both efforts in a "merger project" resulting in a global monogenic PD cohort with build-up of a sustainable infrastructure to identify the multi-ancestry spectrum of monogenic PD and enable studies of factors modifying penetrance and expression of monogenic PD. This effort demonstrates the value of future research based on team science approaches to generate comprehensive and globally relevant results.
Open AccessUnderstanding monogenic Parkinson's disease at a global scale
Until recently, about three-quarters of all monogenic Parkinson's disease (PD) studies were performed in European/White ancestry, thereby severely limiting our insights into genotype-phenotype relationships at global scale. The first systematic approach to embrace monogenic PD worldwide, The Michael J. Fox Foundation Global Monogenic PD (MJFF GMPD) Project, contacted authors of publications reporting individuals carrying pathogenic variants in known PD-causing genes. In contrast, the Global Parkinson's Genetics Program's (GP2) Monogenic Network took a different approach by targeting PD centers not yet represented in the medical literature. Here, we describe combining both efforts in a "merger project" resulting in a global monogenic PD cohort with build-up of a sustainable infrastructure to identify the multi-ancestry spectrum of monogenic PD and enable studies of factors modifying penetrance and expression of monogenic PD. This effort demonstrates the value of future research based on team science approaches to generate comprehensive and globally relevant results.
- Open Access
- 3 October 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (10) , e0292180
Establishing an online resource to facilitate global collaboration and inclusion of underrepresented populations: Experience from the MJFF Global Genetic Parkinson’s Disease Project
Parkinson’s disease (PD) is the fastest-growing neurodegenerative disorder, currently affecting ~7 million people worldwide. PD is clinically and genetically heterogeneous, with at least 10% of all cases explained by a monogenic cause or strong genetic risk factor. However, the vast majority of our present data on monogenic PD is based on the investigation of patients of European White ancestry, leaving a large knowledge gap on monogenic PD in underrepresented populations. Gene-targeted therapies are being developed at a fast pace and have started entering clinical trials. In light of these developments, building a global network of centers working on monogenic PD, fostering collaborative research, and establishing a clinical trial-ready cohort is imperative. Based on a systematic review of the English literature on monogenic PD and a successful team science approach, we have built up a network of 59 sites worldwide and have collected information on the availability of data, biomaterials, and facilities. To enable access to this resource and to foster collaboration across centers, as well as between academia and industry, we have developed an interactive map and online tool allowing for a quick overview of available resources, along with an option to filter for specific items of interest. This initiative is currently being merged with the Global Parkinson’s Genetics Program (GP2), which will attract additional centers with a focus on underrepresented sites. This growing resource and tool will facilitate collaborative research and impact the development and testing of new therapies for monogenic and potentially for idiopathic PD patients.
- 3 October 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (10) , e0292180
Open AccessEstablishing an online resource to facilitate global collaboration and inclusion of underrepresented populations: Experience from the MJFF Global Genetic Parkinson’s Disease Project
Parkinson’s disease (PD) is the fastest-growing neurodegenerative disorder, currently affecting ~7 million people worldwide. PD is clinically and genetically heterogeneous, with at least 10% of all cases explained by a monogenic cause or strong genetic risk factor. However, the vast majority of our present data on monogenic PD is based on the investigation of patients of European White ancestry, leaving a large knowledge gap on monogenic PD in underrepresented populations. Gene-targeted therapies are being developed at a fast pace and have started entering clinical trials. In light of these developments, building a global network of centers working on monogenic PD, fostering collaborative research, and establishing a clinical trial-ready cohort is imperative. Based on a systematic review of the English literature on monogenic PD and a successful team science approach, we have built up a network of 59 sites worldwide and have collected information on the availability of data, biomaterials, and facilities. To enable access to this resource and to foster collaboration across centers, as well as between academia and industry, we have developed an interactive map and online tool allowing for a quick overview of available resources, along with an option to filter for specific items of interest. This initiative is currently being merged with the Global Parkinson’s Genetics Program (GP2), which will attract additional centers with a focus on underrepresented sites. This growing resource and tool will facilitate collaborative research and impact the development and testing of new therapies for monogenic and potentially for idiopathic PD patients.
- Open Access
- 24 January 2023
- Published by Wiley in Movement Disorders
- Vol. 38 (2) , 286-303
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort
Background: As gene‐targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial‐ready cohorts is limited.Objective: The objectives are to (1) establish an international cohort of affected and unaffected individuals with PD‐linked variants; (2) provide harmonized and quality‐controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD.Methods: We conducted a worldwide, systematic online survey to collect individual‐level data on individuals with PD‐linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ‐1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype–phenotype relationships were analyzed.Results: We collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ‐1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published.Conclusions: Within the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD‐linked variants; (2) provide harmonized and quality‐controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene‐targeted clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 24 January 2023
- Published by Wiley in Movement Disorders
- Vol. 38 (2) , 286-303
Open AccessEmbracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort
Background: As gene‐targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial‐ready cohorts is limited.Objective: The objectives are to (1) establish an international cohort of affected and unaffected individuals with PD‐linked variants; (2) provide harmonized and quality‐controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD.Methods: We conducted a worldwide, systematic online survey to collect individual‐level data on individuals with PD‐linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ‐1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype–phenotype relationships were analyzed.Results: We collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ‐1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published.Conclusions: Within the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD‐linked variants; (2) provide harmonized and quality‐controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene‐targeted clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 15 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (15) , eabm5016
One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk
With newly rising coronavirus disease 2019 (COVID-19) cases, important data gaps remain on (i) long-term dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection rates in fixed cohorts (ii) identification of risk factors, and (iii) establishment of effective surveillance strategies. By polymerase chain reaction and antibody testing of 1% of the local population and >90,000 app-based datasets, the present study surveilled a catchment area of 300,000 inhabitants from March 2020 to February 2021. Cohort (56% female; mean age, 45.6 years) retention was 75 to 98%. Increased risk for seropositivity was detected in several high-exposure groups, especially nurses. Unreported infections dropped from 92 to 29% during the study. “Contact to COVID-19–affected” was the strongest risk factor, whereas public transportation, having children in school, or tourism did not affect infection rates. With the first SARS-CoV-2 cohort study, we provide a transferable model for effective surveillance, enabling monitoring of reinfection rates and increased preparedness for future pandemics.
- 15 April 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (15) , eabm5016
Open AccessOne-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk
With newly rising coronavirus disease 2019 (COVID-19) cases, important data gaps remain on (i) long-term dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection rates in fixed cohorts (ii) identification of risk factors, and (iii) establishment of effective surveillance strategies. By polymerase chain reaction and antibody testing of 1% of the local population and >90,000 app-based datasets, the present study surveilled a catchment area of 300,000 inhabitants from March 2020 to February 2021. Cohort (56% female; mean age, 45.6 years) retention was 75 to 98%. Increased risk for seropositivity was detected in several high-exposure groups, especially nurses. Unreported infections dropped from 92 to 29% during the study. “Contact to COVID-19–affected” was the strongest risk factor, whereas public transportation, having children in school, or tourism did not affect infection rates. With the first SARS-CoV-2 cohort study, we provide a transferable model for effective surveillance, enabling monitoring of reinfection rates and increased preparedness for future pandemics.
- 18 January 2021
- Published by Wiley in European Journal of Neurology
- Vol. 28 (6) , E35-E36
Letter to the Editor about the Ongre et al. publication: ‘Progression of fatigue in Parkinson's disease—a 9‐year follow‐up’ (Eur J Neurol 2020. doi: 10.1111/ene.14520)
With great interest we read the article “Progression of fatigue in Parkinson's disease ‐ a 9‐year follow‐up” by Ongre et al.(1). The authors compared the course of fatigue in subjects with Parkinson’s disease (PD) and a healthy control group identifying higher fatigue rates in PD patients, along with several factors associated with fatigue.
- 18 January 2021
- Published by Wiley in European Journal of Neurology
- Vol. 28 (6) , E35-E36
Letter to the Editor about the Ongre et al. publication: ‘Progression of fatigue in Parkinson's disease—a 9‐year follow‐up’ (Eur J Neurol 2020. doi: 10.1111/ene.14520)
With great interest we read the article “Progression of fatigue in Parkinson's disease ‐ a 9‐year follow‐up” by Ongre et al.(1). The authors compared the course of fatigue in subjects with Parkinson’s disease (PD) and a healthy control group identifying higher fatigue rates in PD patients, along with several factors associated with fatigue.
- Open Access
- 14 December 2020
- Published by Wiley in Movement Disorders
- Vol. 36 (4) , 1005-1010
The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings
Background: Genetic stratification of Parkinson's disease (PD) patients facilitates gene‐tailored research studies and clinical trials. The objective of this study was to describe the design of and the initial data from the Rostock International Parkinson's Disease (ROPAD) study, an epidemiological observational study aiming to genetically characterize ~10,000 participants.Methods: Recruitment criteria included (1) clinical diagnosis of PD, (2) relative of participant with a reportable LRRK2 variant, or (3) North African Berber or Ashkenazi Jew. DNA analysis involved up to 3 successive steps: (1) variant (LRRK2) and gene (GBA) screening, (2) panel sequencing of 68 PD‐linked genes, and (3) genome sequencing.Results: Initial data based on the first 1360 participants indicated that the ROPAD enrollment strategy revealed a genetic diagnostic yield of ~14% among a PD cohort from tertiary referral centers.Conclusions: The ROPAD screening protocol is feasible for high‐throughput genetic characterization of PD participants and subsequent prioritization for gene‐focused research efforts and clinical trials. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 14 December 2020
- Published by Wiley in Movement Disorders
- Vol. 36 (4) , 1005-1010
Open AccessThe Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings
Background: Genetic stratification of Parkinson's disease (PD) patients facilitates gene‐tailored research studies and clinical trials. The objective of this study was to describe the design of and the initial data from the Rostock International Parkinson's Disease (ROPAD) study, an epidemiological observational study aiming to genetically characterize ~10,000 participants.Methods: Recruitment criteria included (1) clinical diagnosis of PD, (2) relative of participant with a reportable LRRK2 variant, or (3) North African Berber or Ashkenazi Jew. DNA analysis involved up to 3 successive steps: (1) variant (LRRK2) and gene (GBA) screening, (2) panel sequencing of 68 PD‐linked genes, and (3) genome sequencing.Results: Initial data based on the first 1360 participants indicated that the ROPAD enrollment strategy revealed a genetic diagnostic yield of ~14% among a PD cohort from tertiary referral centers.Conclusions: The ROPAD screening protocol is feasible for high‐throughput genetic characterization of PD participants and subsequent prioritization for gene‐focused research efforts and clinical trials. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 2 June 2019
- Published by Wiley in Annals of Neurology
- Vol. 86 (2) , 153-157
Using global team science to identify genetic parkinson's disease worldwide
- 2 June 2019
- Published by Wiley in Annals of Neurology
- Vol. 86 (2) , 153-157
Using global team science to identify genetic parkinson's disease worldwide